On July 25, 2017, Biogen (NASDAQ:BIIB) reported better-than-expected Q2 2017 results, fueled by a solid performance from the key growth drivers in the Multiple Sclerosis franchise and thanks to an excellent launch of Spinraza.
The stock closed slightly down, despite a strong beat at EPS level, because the management’s comments during the conference call haven’t taken well by the market.
Q2 2017 results
Biogen reported Q2 2017 sales of $3.08B, 9% ahead of consensus expectation, while EPS of $5.04 were 14.5% higher than consensus, driven by a higher Gross Margin compared to street expectations.
